Trials / Conditions / First-line Treatment

First-line Treatment

19 registered clinical trials studyying First-line Treatment — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatell NCT07500298	M.D. Anderson Cancer Center	Phase 1
Recruiting	Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC NCT06981325	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Recruiting	Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSE NCT06907342	St. Olavs Hospital	Phase 2
Recruiting	Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Tr NCT07117435	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1
Not Yet Recruiting	Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Pros NCT06750952	Sun Yat-sen University	Phase 2
Not Yet Recruiting	Exercise in Patients With Advanced Non-small Cell Lung Cancer NCT06374160	University Hospital, Essen	N/A
Active Not Recruiting	A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma NCT05808608	Hao Zeng	Phase 1 / Phase 2
Recruiting	Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical NCT06278870	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 3
Active Not Recruiting	A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma NCT05256472	Akeso	Phase 2
Unknown	Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma NCT05913661	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Unknown	Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma NCT05760053	Sun Yat-sen University	Phase 2
Recruiting	Can Digitally Delivered First-line Osteoarthritis Treatment Improve Equal Access to Care NCT06148779	Joint Academy	—
Unknown	Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients NCT05221775	Tianjin Medical University Cancer Institute and Hospital	Phase 1
Unknown	Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC NCT05077839	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Active Not Recruiting	Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat NCT04836728	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Completed	Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) NCT04271813	Shanghai Changzheng Hospital	Phase 2
Unknown	Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NS NCT03987867	Tianjin Medical University Cancer Institute and Hospital	Phase 1
Completed	POSITIVE - Study (Part III) Heidelberg NCT02055508	German Cancer Research Center	N/A
Completed	Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer NCT01980212	Hunan Province Tumor Hospital	—